Schiff Nutrition International, Inc. Appoints Brian T. Swette to Its Board of Directors
2011年11月30日 - 6:10AM
ビジネスワイヤ(英語)
Schiff Nutrition International, Inc., (NYSE:WNI), appointed
Brian T. Swette, 57, to its board of directors.
Eric Weider, Schiff Nutrition’s chairman, said: “Brian’s more
than 30 years of broad-based leadership experience makes him a
strong addition to Schiff’s board of directors. We welcome him
aboard.”
“Brian’s combination of consumer marketing, e-commerce and
business operations experience will be valuable assets to Schiff as
we pursue our growth strategy, especially our plan to build premium
brands,” stated Tarang Amin, president and chief executive officer
of Schiff Nutrition.
Swette added, “I am pleased to join Schiff’s board of directors.
The company has assembled a world-class leadership team and I look
forward to helping the company achieve its objectives.”
Brian T. Swette serves on the Board of Directors of Jamba, Inc.,
Care.com, The FRS Company and Shutterfly. He previously served on
the boards of Burger King and The Ladders.com. Swette was formerly
eBay's Chief Operating Officer, where he oversaw international
expansion, marketing and customer support initiatives that made
eBay the most accessible and successful e-commerce site on the
Internet. Prior to joining eBay, Swette was Executive Vice
President and Chief Marketing Officer for the Pepsi-Cola Company.
During his 17-year tenure, he was responsible for the worldwide
marketing and advertising efforts for all Pepsi-Cola brands,
oversaw business strategy, brand architecture and new product
activity. Swette holds a Bachelor's degree in Economics from
Arizona State University.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Schiff Move Free®, Schiff® Vitamins, Schiff MegaRed®,
Schiff Mega-D3®, Tiger's Milk®, Schiff Sustenex®, and Schiff
Digestive Advantage®. To learn more about Schiff, please visit the
web site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
dependence on sales of Schiff Move Free product and the joint care
category, dependence on sales of Schiff MegaRed product, dependence
on individual customers, adverse publicity or consumer perception
regarding our nutritional supplements and/or their ingredients,
similar products distributed by other companies or the nutritional
supplement industry generally, the impact of competitive products
and pricing pressure (including expansion of private label
products), the inability to successfully bid on new and existing
private label business, the impact of raw material pricing,
availability and quality (particularly relating to joint care
products and ingredients from third-party suppliers outside the
United States, including China), claims that our products infringe
the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully
launch and maintain sales (especially in the joint care and omega-3
categories) outside of the United States while maintaining the
integrity of the products sold and complying with local
regulations, the inability to appropriately respond to changing
consumer preferences and demand for new products, the inability to
gain or maintain market distribution for new products or product
enhancements, including products in the probiotic space, litigation
and government or administrative regulatory action in the United
States and internationally, including FDA enforcement and product
liability claims, the inability or increased cost to obtain
sufficient levels of product liability and general insurance, the
inability to comply with existing or new regulations, both in the
United States and abroad, and adverse actions regarding product
formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our
manufacturing operations, the inability to find strategic
transaction opportunities or the inability to successfully
consummate or integrate a strategic transaction (including the
inability to successfully integrate the assets recently acquired
from Ganeden), the inability to maintain or attract key personnel,
interruptions to our information technology systems, control by our
principal stockholders, and other factors indicated from time to
time in the company’s SEC reports, copies of which are available
upon request from the company’s investor relations department or
may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should
be carefully considered before making an investment decision with
respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
過去 株価チャート
から 4 2024 まで 5 2024
Schiff Nutrit (NYSE:WNI)
過去 株価チャート
から 5 2023 まで 5 2024